Castle Creek Biosciences, LLC

Castle Creek Biosciences, LLC is a United States-based clinical-stage biotechnology company focused on cell and gene therapy. Headquartered at 405 Eagleview Boulevard in Exton, Pennsylvania, the company describes itself as a late-stage developer of re-dosable gene therapies intended to treat genetic diseases. Its stated mission is to create transformative therapies that improve the lives of people living with genetic diseases, and its work is inspired by patients and families affected by dystrophic epidermolysis bullosa (DEB), a rare and devastating genetic skin condition with limited treatment options. The company's lead candidate is D-Fi, a gene therapy in a registrational Phase 3 clinical trial for patients with DEB. Castle Creek positions itself around a distinctive therapeutic approach tailored to the unique needs of each targeted indication, and it maintains a pipeline of programs aimed at genetic diseases. The company operates as a portfolio company of Paragon Biosciences, a global life science organization that creates, builds, and funds innovative biology-based companies and accelerates scientific breakthroughs to treat and cure diseases. Leadership includes Matthew Gantz, M.B.A., who serves as Chairman and Chief Executive Officer and has publicly articulated the company's ambition to build a leading cell and gene therapy company for patients and families. The leadership team also includes David Chu, M.D., Ph.D., F.A.A.D., as Chief Medical Officer, and Matthew Crabtree as Vice President, Finance. Castle Creek engages with the patient community and advocacy organizations such as debra—The Dystrophic Epidermolysis Bullosa Research Association of America and the EB Research Partnership, whose families have been featured in the company's communications. As a privately held portfolio company within the Paragon Biosciences group, Castle Creek Biosciences does not trade on a public stock exchange. Its activities center on clinical development, regulatory progress toward potential approval of D-Fi, and advancing its broader gene therapy pipeline. The company provides medical information contact channels for its investigational therapies and clinical studies, and it maintains media relations through Paragon Biosciences.

Castle Creek Biosciences, LLC is a United States-based biotechnology company located in Exton, Pennsylvania. Public information about the company is primarily drawn from its official website and corporate disclosures, which describe it as a late-stage cell and gene therapy company developing re-dosable gene therapies for genetic diseases. The company operates as a portfolio company of Paragon Biosciences, a global life science organization that creates, builds, and funds innovative biology-based companies. The company's therapeutic focus centers on dystrophic epidermolysis bullosa (DEB), a rare genetic skin disease with limited treatment options. Castle Creek states that people affected by DEB inspired its development of an innovative therapy for the condition. Its lead candidate, D-Fi, is in a registrational Phase 3 clinical trial for patients with DEB. The company describes its approach as tailoring therapeutic strategies to the unique needs of each targeted indication and maintains a pipeline of programs for genetic diseases. Leadership at Castle Creek includes Matthew Gantz, M.B.A., as Chairman and Chief Executive Officer; David Chu, M.D., Ph.D., F.A.A.D., as Chief Medical Officer; and Matthew Crabtree as Vice President, Finance. Gantz has articulated the company's goal of building a leading cell and gene therapy company for patients and families seeking relief from devastating genetic diseases. Castle Creek engages with patient advocacy organizations, including debra—The Dystrophic Epidermolysis Bullosa Research Association of America and the EB Research Partnership. The company's headquarters is at 405 Eagleview Boulevard, Exton, PA 19341, and it provides contact channels for media inquiries and medical information regarding its investigational therapies and clinical studies. As a private portfolio company of Paragon Biosciences, Castle Creek does not have publicly traded equity.

• Castle Creek Biosciences is conducting a registrational Phase 3 trial of D-Fi for patients with dystrophic epidermolysis bullosa (DEB).

Late-stage cell and gene therapy company developing re-dosable gene therapies for genetic diseases, with a patient-centered mission and a lead registrational program in DEB.

• D-Fi

  Lead gene therapy candidate in a registrational Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa (DEB).

1. 1Castle Creek Biosciences: Cell and Gene Therapy Companycastlecreekbio.com
2. 2Castle Creek: A Regenerative Medicine Companycastlecreekbio.com
3. 3Castle Creek: Experience, Expertise and Proven Processescastlecreekbio.com
4. 4Contact Us - Castle Creek Biosciences, Inc.castlecreekbio.com
5. 5Castle Creek Biosciences, LLC (United States) - Wikidatawikidata.org
6. 6Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officerprnewswire.com